How Low Should We Go? The Search for Balance in Management of Small Human Epidermal Growth Factor Receptor 2–Positive Breast Cancers
Menées sur deux cohortes de patientes atteintes d'un cancer localisé du sein HER2+ sans envahissement ganglionnaire (durées médianes de suivi : 5,8 et 5,5 ans), ces deux études évaluent l'efficacité des traitements adjuvants
The articles that accompany this editorial feature work from two independent groups and provide important data for consideration by clinicians who treat small human epidermal growth factor receptor 2 (HER2) –positive breast cancers. Fehrenbacher et al present an analysis of outcomes among women with small, node-negative, HER2-positive tumors treated in the Kaiser Permanente Northern California system from 2000 to 2006, whereas Vaz-Luis et al present data from a similar cohort treated at National Comprehensive Cancer Network (NCCN) centers over a longer time period that spans the dissemination of trastuzumab into adjuvant breast cancer care...
Journal of Clinical Oncology , éditorial en libre accès, 2014